[{"indications": "Indications\u00a0attention deficit hyperactivity disorder (under specialist supervision);\r\nnarcolepsy [unlicensed indication]", "name": "METHYLPHENIDATE HYDROCHLORIDE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.4 CNS\r\nstimulants and drugs used for attention deficit hyperactivity disorder", "METHYLPHENIDATE HYDROCHLORIDE", "Modified release"], "cautions": "Cautions\u00a0\n(From 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder: British National Formulary)\nDrug treatment of ADHD should be part of a comprehensive treatment programme. The choice of medication should take into consideration co-morbid conditions (such as tic disorders, Tourette syndrome, and epilepsy), the adverse effect profile, potential for drug misuse, and preferences of the patient and carers. Methylphenidate and atomoxetine are used for the management of ADHD; dexamfetamine is an alternative in children who do not respond to these drugs. Before initiation of drug therapy, and every 6 months thereafter, pulse, blood pressure, weight, and height should be measured.The need to continue drug treatment for ADHD should be reviewed at least annually. This may involve suspending treatment.; also monitor for psychiatric disorders; anxiety or agitation; tics or a family history of Tourette syndrome; drug or alcohol dependence; epilepsy (discontinue if increased seizure frequency); susceptibility to angle-closure glaucoma; avoid abrupt withdrawal; interactions: Appendix 1 (sympathomimetics)", "side-effects": "Side-effects\u00a0abdominal pain, nausea, vomiting, diarrhoea, dyspepsia,\r\ndry mouth, anorexia, reduced weight gain; tachycardia, palpitation,\r\narrhythmias, changes in blood pressure; cough, nasopharyngitis; tics\r\n(very rarely Tourette syndrome), insomnia, nervousness,\r\nasthenia, depression, irritability, aggression, headache, drowsiness,\r\ndizziness, movement disorders; fever; arthralgia; rash, pruritus,\r\nalopecia; growth restriction; less commonly constipation,\r\ndyspnoea, abnormal dreams, confusion, suicidal ideation, urinary frequency,\r\nhaematuria, muscle cramps, epistaxis; rarely angina,\r\nsweating, and visual disturbances; very rarely hepatic\r\ndysfunction, myocardial infarction, cerebral arteritis, psychosis,\r\nneuroleptic malignant syndrome, tolerance and dependence, blood disorders\r\nincluding leucopenia and thrombocytopenia, angle-closure glaucoma,\r\nexfoliative dermatitis, and erythema multiforme; supraventricular\r\ntachycardia, bradycardia, and convulsions also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129249.htm", "doses": ["Attention deficit hyperactivity disorder, adult over 18 years [unlicensed use], 5\u00a0mg 2\u20133 times\r\ndaily increased if necessary at weekly intervals according to response,\r\nmax. 100\u00a0mg daily in 2\u20133 divided doses; child 6\u201318 years, initially 5\u00a0mg 1\u20132 times daily, increased if necessary\r\nat weekly intervals by 5\u201310\u00a0mg daily; usual max. 60\u00a0mg daily in 2\u20133\r\ndivided doses but may be increased to 2.1\u00a0mg/kg daily in 2\u20133 divided\r\ndoses (max. 90\u00a0mg daily) under the direction of a specialist; discontinue\r\nif no response after 1 month; child 4\u20136 years see BNF for Children", "If effect wears off in evening (with\r\nrebound hyperactivity) a dose at bedtime may be appropriate (establish\r\nneed with trial bedtime dose)", "Treatment may be started using a modified-release\r\npreparation", "Narcolepsy [unlicensed indication], 10\u201360\u00a0mg (usually 20\u201330\u00a0mg)\r\ndaily in divided doses before meals", "Name[Equasym XL\u00ae (Shire) ] Capsules, m/r, methylphenidate hydrochloride\r\n10\u00a0mg (white/green), net price 30-cap pack = \u00a325.00; 20\u00a0mg (white/blue),\r\n30-cap pack = \u00a330.00; 30\u00a0mg (white/brown), 30-cap pack = \u00a335.00. \r\n    Label:\r\n    25Note\u00a0Equasym XL\u00ae capsules consist\r\nof an immediate-release component (30% of the dose) and a modified-release\r\ncomponent (70% of the dose)Dose\u00a0attention deficit hyperactivity disorder, adult over 18 years [unlicensed use], initially 10\u00a0mg\r\nonce daily in the morning before breakfast, increased gradually at\r\nweekly intervals if necessary, max. 100\u00a0mg daily; child 6\u201318 years, initially 10\u00a0mg once daily in the morning before breakfast,\r\nincreased gradually at weekly intervals if necessary, usual max. 60\u00a0mg\r\ndaily but may be increased to 2.1\u00a0mg/kg daily (max. 90\u00a0mg daily) [unlicensed]\r\nunder the direction of a specialist; discontinue if no response after\r\n1 monthNote\u00a0Contents of capsule can be sprinkled on a\r\ntablespoon of apple sauce (then swallowed immediately without chewing)"], "pregnancy": "Pregnancy\u00a0limited experience\u2014avoid unless potential benefit\r\noutweighs risk"}, {"indications": "Indications\u00a0attention deficit hyperactivity disorder (under specialist supervision);\r\nnarcolepsy [unlicensed indication]", "name": "METHYLPHENIDATE HYDROCHLORIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.4 CNS\r\nstimulants and drugs used for attention deficit hyperactivity disorder", "METHYLPHENIDATE HYDROCHLORIDE"], "cautions": "Cautions\u00a0\n(From 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder: British National Formulary)\nDrug treatment of ADHD should be part of a comprehensive treatment programme. The choice of medication should take into consideration co-morbid conditions (such as tic disorders, Tourette syndrome, and epilepsy), the adverse effect profile, potential for drug misuse, and preferences of the patient and carers. Methylphenidate and atomoxetine are used for the management of ADHD; dexamfetamine is an alternative in children who do not respond to these drugs. Before initiation of drug therapy, and every 6 months thereafter, pulse, blood pressure, weight, and height should be measured.The need to continue drug treatment for ADHD should be reviewed at least annually. This may involve suspending treatment.; also monitor for psychiatric disorders; anxiety or agitation; tics or a family history of Tourette syndrome; drug or alcohol dependence; epilepsy (discontinue if increased seizure frequency); susceptibility to angle-closure glaucoma; avoid abrupt withdrawal; interactions: Appendix 1 (sympathomimetics)", "side-effects": "Side-effects\u00a0abdominal pain, nausea, vomiting, diarrhoea, dyspepsia,\r\ndry mouth, anorexia, reduced weight gain; tachycardia, palpitation,\r\narrhythmias, changes in blood pressure; cough, nasopharyngitis; tics\r\n(very rarely Tourette syndrome), insomnia, nervousness,\r\nasthenia, depression, irritability, aggression, headache, drowsiness,\r\ndizziness, movement disorders; fever; arthralgia; rash, pruritus,\r\nalopecia; growth restriction; less commonly constipation,\r\ndyspnoea, abnormal dreams, confusion, suicidal ideation, urinary frequency,\r\nhaematuria, muscle cramps, epistaxis; rarely angina,\r\nsweating, and visual disturbances; very rarely hepatic\r\ndysfunction, myocardial infarction, cerebral arteritis, psychosis,\r\nneuroleptic malignant syndrome, tolerance and dependence, blood disorders\r\nincluding leucopenia and thrombocytopenia, angle-closure glaucoma,\r\nexfoliative dermatitis, and erythema multiforme; supraventricular\r\ntachycardia, bradycardia, and convulsions also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/31969.htm", "doses": ["Attention deficit hyperactivity disorder, adult over 18 years [unlicensed use], 5\u00a0mg 2\u20133 times\r\ndaily increased if necessary at weekly intervals according to response,\r\nmax. 100\u00a0mg daily in 2\u20133 divided doses; child 6\u201318 years, initially 5\u00a0mg 1\u20132 times daily, increased if necessary\r\nat weekly intervals by 5\u201310\u00a0mg daily; usual max. 60\u00a0mg daily in 2\u20133\r\ndivided doses but may be increased to 2.1\u00a0mg/kg daily in 2\u20133 divided\r\ndoses (max. 90\u00a0mg daily) under the direction of a specialist; discontinue\r\nif no response after 1 month; child 4\u20136 years see BNF for Children", "If effect wears off in evening (with\r\nrebound hyperactivity) a dose at bedtime may be appropriate (establish\r\nneed with trial bedtime dose)", "Treatment may be started using a modified-release\r\npreparation", "Narcolepsy [unlicensed indication], 10\u201360\u00a0mg (usually 20\u201330\u00a0mg)\r\ndaily in divided doses before meals"], "pregnancy": "Pregnancy\u00a0limited experience\u2014avoid unless potential benefit\r\noutweighs risk"}]